Replies to post #24954 on Mymetics Corp (MYMX)

[Work Harder]

Altimmune Receives Award from U.S. Department of Defense to Fund Phase 1/2 Clinical Trial of T-COVID™ in Outpatients with Early COVID-19

https://www.globenewswire.com/news-release/2020/06/29/2054563/0/en/Altimmune-Receives-Award-from-U-S-Department-of-Defense-to-Fund-Phase-1-2-Clinical-Trial-of-T-COVID-in-Outpatients-with-Early-COVID-19.html

U.S. Army Medical Research & Development Command

The competitive award was granted by USAMRDC in collaboration with the Medical Technology Enterprise Consortium (MTEC), a 501(c)(3) biomedical technology consortium working in partnership with the Department of Defense (DoD). The award is expected to provide Altimmune sufficient funding to cover the entire cost of conducting this clinical trial.

https://www.gdit.com/about-gdit/leadership/

Unknown Future for Frederick Vaccine Company After Recent .

https://biobuzz.io/unknown-future-for-frederick-vaccine-company-after-recent-acquisition-by-general-dynamics/

Harrington Discovery Institute to award Columbia University funding to develop intransasal agent to block COVID-19

https://webcache.googleusercontent.com/search?q=cache:6I1OHhYh0XkJ:https://www.bioworld.com/content/grants-2020+&cd=3&hl=en&ct=clnk&gl=us

https://www.uhhospitals.org/harrington-discovery-institute/about-us

[Work Harder]

MVA-SARS-2-S

Ludwig-Maximilians, University of Munich

https://www.sciencedirect.com/science/article/pii/S2667325821000212

MVA SARS-CoV-2 vaccine candidate shows strong immunogenicity in preclinical trials

https://www.news-medical.net/news/20210114/MVA-SARS-CoV-2-vaccine-candidate-shows-strong-immunogenicity-in-preclinical-trials.aspx

https://www.biorxiv.org/content/10.1101/2021.01.09.426032v1

Bart L Haagmans

https://pubmed.ncbi.nlm.nih.gov/33577765/

Rogier W Sanders Bart L Haagmans

Conflict of interest statement

Declaration of interests N.P.K. is a co-founder, shareholder, and chair of the scientific advisory board of Icosavax. The remaining authors declare no competing interests. Amsterdam UMC has filed a patent application concerning the SARS-CoV-2 mAbs used here (Brouwer et al., 2020). N.P.K. has a nonprovisional US patent (no. 14/930,792) related to I53-50 (Bale et al., 2016).

https://www.fiercebiotech.com/biotech/icosavax-raises-100m-to-take-rsv-covid-19-vaccines-into-clinic

Icosavax lands $100M to take its virus-like particle vaccines into clinical trials

RA Capital

Icosavax is a Univ. of Wash.-spinout

https://medcitynews.com/2021/04/icosavax-lands-100m-to-take-its-virus-like-particle-vaccines-into-clinical-trials/

The financing was led by RA Capital Management

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=163833450